Statin is a reasonable treatment option for patients with polycystic ovary syndrome: A meta-analysis of randomized controlled trials

Experimental and Clinical Endocrinology and Diabetes

Volumn 120, Issue 6, 2012, Pages 367-375

  Gao, L ^a   Zhao, F L ^a   Li, S C ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

hydroxymethylglutaryl CoA reductase inhibitors; meta analysis; Polycystic Ovary Syndrome (PCOS)

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; FOLLITROPIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN; LUTEINIZING HORMONE; METFORMIN; PLACEBO; PROLACTIN; SIMVASTATIN; TESTOSTERONE; TRIACYLGLYCEROL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; HUMAN; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; META ANALYSIS; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TESTOSTERONE BLOOD LEVEL; TREATMENT INDICATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ALGORITHMS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; METFORMIN; PLACEBOS; POLYCYSTIC OVARY SYNDROME; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84862202703     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0032-1304619     Document Type: Article

References (35)

1. March W A, Moore VM, Willson K J et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Human Reproduction: 2010; 25 544 551
2. Mehrabian F, Khani B, Kelishadi R et al. The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria. Endokrynologia Polska: 2011; 62 238 242
3. Alexander C J, Tangchitnob E P, Lepor N E. Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. Reviews in Cardiovascular Medicine: 2009; 10 83 90
4. Giallauria F, Orio F, Palomba S et al. Cardiovascular risk in women with polycystic ovary syndrome. J Cardiovasc Med (Hagerstown): 2008; 9 987 992
5. Lo J C, Feigenbaum S L, Yang J et al. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab: 2006; 91 1357 1363
6. Diamanti-Kandarakis E, Papavassiliou A G, Kandarakis S A et al. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab: 2007; 18 280 285 (Pubitemid 47332216)
7. Legro R S, Kunselman A R, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med: 2001; 111 607 613 (Pubitemid 34088070)
8. Berneis K, Rizzo M, Hersberger M. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrom. Int J Clin Pract: 2009; 63 56 62
9. Dahlgren E, Janson P O, Johansson S et al. Polycystic-Ovary-Syndrome and Risk for Myocardial-Infarction - Evaluated from a Risk Factor Model Based on a Prospective Population Study of Women. Acta Obstetricia Et Gynecologica Scandinavica: 1992; 71 599 604 (Pubitemid 23050339)
10. Ando H, Takamura T, Ota T et al. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther: 2000; 294 1043 1046 (Pubitemid 30666857)
11. Wassmann S, Laufs U, Muller K et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol: 2002; 22 300 305 (Pubitemid 34127043)
12. Pedersen T R, Kjekshus J, Berg K et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4 S). 1994. Atheroscler Suppl: 2004; 5 81 87
13. Sacks F M, Pfeffer M A, Moye L A et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med: 1996; 335 1001 1009 (Pubitemid 26338729)
14. Shepherd J, Cobbe S M, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med: 1995; 333 1301 1307
15. Banaszewska B, Pawelczyk L, Spaczynski R Z et al. Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. J Clin Endocrinol Metab: 2009; 94 4938 4945
16. Banaszewska B, Pawelczyk L, Spaczynski R Z et al. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J Clin Endocrinol Metab: 2007; 92 456 461
17. Duleba A J, Banaszewska B, Spaczynski R Z et al. Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility: 2006; 85 996 1001
18. Kazerooni T, Azam S, Sedigheh D et al. Effects of metforimin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study. Fertility and Sterility: 2010; 94 2208 2213
19. Raja-Khan N, Kunselman A R, Hogeman C S et al. Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility: 2011; 95 1849 1852
20. Sathyapalan T, Kilpatrick E S, Coady A M et al. The Effect of Atorvastatin in Patients with Polycystic Ovary Syndrome: A Randomized Double-Blind Placebo-Controlled Study. J Clin Endocrinol Metab: 2009; 94 103 108
21. Sathyapalan T, Kilpatrick E S, Coady A M et al. Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf): 2010; 72 566 568
22. Cemil K, Sevim D, Biilent B. Compatative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study. Fertility and Sterility: 2009; 92 635 642
23. Collier E, Carpentier J L, Beitz L et al. Specific glycosylation site mutations of the insulin receptor alpha subunit impair intracellular transport. Biochemistry: 1993; 32 7818 7823 (Pubitemid 23240829)
24. Hwang J B, Frost S C. Effect of alternative glycosylation on insulin receptor processing. J Biol Chem: 1999; 274 22813 22820
25. Lee W C, Choi C H, Cha S H et al. Role of ERK in hydrogen peroxide-induced cell death of human glioma cells. Neurochem Res: 2005; 30 263 270 (Pubitemid 40569210)
26. Kelly C C, Lyall H, Petrie J R et al. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab: 2001; 86 2453 2455 (Pubitemid 32545690)
27. Diamanti-Kandarakis E, Paterakis T, Alexandraki K et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Human Reproduction: 2006; 21 1426 1431 (Pubitemid 44445017)
28. Ehrmann D A, Barnes R B, Rosenfield R L et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care: 1999; 22 141 146 (Pubitemid 29028311)
29. Baracat E C, Maciel GA R, Junior JM S et al. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertility and Sterility: 2004; 81 355 360 (Pubitemid 38223916)
30. Tang T, Lord J M, Norman R J et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev: 2010; CD003053
31. Diamanti-Kandarakis E, Alexandraki K, Protogerou A et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol: 2005; 152 749 756 (Pubitemid 40744544)
32. Moghetti P, Castello R, Negri C et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab: 2000; 85 139 146 (Pubitemid 32268804)
33. Morin-Papunen L C, Koivunen R M, Ruokonen A et al. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertility and Sterility: 1998; 69 691 696 (Pubitemid 28188465)
34. Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero J I et al. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab: 2007; 92 2453 2461 (Pubitemid 47037342)
35. Carmina E, Rosato F, Janni A et al. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab: 2006; 91 2 6 (Pubitemid 43069106)